LU91651I2 - Produits médicinaux contenent de l'indacatérol ou un sel de celui-ci (ONBREZ BREEZHALER®) - Google Patents
Produits médicinaux contenent de l'indacatérol ou un sel de celui-ci (ONBREZ BREEZHALER®)Info
- Publication number
- LU91651I2 LU91651I2 LU91651C LU91651C LU91651I2 LU 91651 I2 LU91651 I2 LU 91651I2 LU 91651 C LU91651 C LU 91651C LU 91651 C LU91651 C LU 91651C LU 91651 I2 LU91651 I2 LU 91651I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- indacaterol
- salt
- medicinal products
- products contain
- onbrez
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
- C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9913083.3A GB9913083D0 (en) | 1999-06-04 | 1999-06-04 | Organic compounds |
PCT/EP2000/005058 WO2000075114A1 (fr) | 1999-06-04 | 2000-06-02 | Agonistes du recepteur beta 2-adrenergique |
Publications (2)
Publication Number | Publication Date |
---|---|
LU91651I2 true LU91651I2 (fr) | 2010-04-19 |
LU91651I9 LU91651I9 (fr) | 2019-01-03 |
Family
ID=10854788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91651C LU91651I2 (fr) | 1999-06-04 | 2010-02-17 | Produits médicinaux contenent de l'indacatérol ou un sel de celui-ci (ONBREZ BREEZHALER®) |
Country Status (38)
Country | Link |
---|---|
US (9) | US6878721B1 (fr) |
EP (2) | EP1183240B1 (fr) |
JP (1) | JP3785365B2 (fr) |
KR (1) | KR100718615B1 (fr) |
CN (1) | CN1156451C (fr) |
AR (1) | AR035548A1 (fr) |
AT (1) | ATE440083T1 (fr) |
AU (1) | AU765919B2 (fr) |
BE (1) | BE2010C011I2 (fr) |
BR (1) | BRPI0011324B8 (fr) |
CA (1) | CA2375810C (fr) |
CO (1) | CO5170518A1 (fr) |
CY (3) | CY1109604T1 (fr) |
CZ (1) | CZ302403B6 (fr) |
DE (2) | DE60042781D1 (fr) |
DK (2) | DK2332915T3 (fr) |
ES (2) | ES2331457T3 (fr) |
FR (1) | FR10C0006I2 (fr) |
GB (1) | GB9913083D0 (fr) |
HK (2) | HK1045837B (fr) |
HU (1) | HU227034B1 (fr) |
IL (2) | IL146578A0 (fr) |
LU (1) | LU91651I2 (fr) |
MX (1) | MXPA01012474A (fr) |
MY (1) | MY126951A (fr) |
NL (1) | NL300437I1 (fr) |
NO (2) | NO322944B1 (fr) |
NZ (1) | NZ515669A (fr) |
PE (1) | PE20010219A1 (fr) |
PL (1) | PL198847B1 (fr) |
PT (2) | PT2332915E (fr) |
RU (1) | RU2244709C2 (fr) |
SI (1) | SI1183240T1 (fr) |
SK (1) | SK287260B6 (fr) |
TR (1) | TR200103497T2 (fr) |
TW (1) | TWI253447B (fr) |
WO (1) | WO2000075114A1 (fr) |
ZA (1) | ZA200109931B (fr) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
GB0121214D0 (en) * | 2001-08-31 | 2001-10-24 | Btg Int Ltd | Synthetic method |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
WO2003042160A1 (fr) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Agonistes de recepteur d'aryl aniline beta-2 adrenergique |
EP2311818B1 (fr) | 2002-02-28 | 2013-01-16 | Novartis AG | Combinaison d'un dérivé de 5-phenylthiazole utile comme inhibiteur de kinase PI3 et d'un composé antiinflammatoire, bronchodilatateur ou d'un antihistaminique. |
US6933410B2 (en) | 2002-03-08 | 2005-08-23 | Novartis Ag | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine |
US7250426B2 (en) * | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
DE10256080A1 (de) * | 2002-11-29 | 2004-06-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropiumhaltige Arzneimittelkombination für die Inhalation |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
TWI324151B (en) * | 2003-04-02 | 2010-05-01 | Novartis Ag | Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones |
GB0307856D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
WO2004087142A1 (fr) * | 2003-04-04 | 2004-10-14 | Novartis Ag | Derives de quinoline-2-one permettant de traiter des maladies des voies respiratoires |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1574501A1 (fr) * | 2004-03-11 | 2005-09-14 | Pfizer Limited | Dérivés de quinoléinone, compositions pharmaceutiques les contenant et leur usage |
WO2005092861A1 (fr) * | 2004-03-11 | 2005-10-06 | Pfizer Limited | Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci |
KR20120091378A (ko) | 2004-03-23 | 2012-08-17 | 노파르티스 아게 | 제약 조성물 |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
GB0413960D0 (en) * | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
WO2006031556A2 (fr) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Composes d'arylaniline a substitution amidine |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0511066D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
GB0511065D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
EP1924553A1 (fr) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Dérivés bicyclo[2.2.]hept-7-ylamine et leurs utilisations |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
JP2009506029A (ja) * | 2005-08-26 | 2009-02-12 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患、特に慢性閉塞性肺疾患(copd)および喘息の処置に使用し得る化合物の組み合わせ |
EP2532677A1 (fr) | 2005-10-21 | 2012-12-12 | Novartis AG | Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques |
TWI392493B (zh) * | 2005-10-26 | 2013-04-11 | Novartis Ag | 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合 |
GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
EP1878722A1 (fr) * | 2006-07-13 | 2008-01-16 | Novartis AG | Dérivés de quinolinone et leur compositions pharmaceutiques |
KR101402398B1 (ko) * | 2006-06-30 | 2014-06-03 | 노파르티스 아게 | 퀴놀리논 유도체 및 이의 제약 조성물 |
EP1914227A1 (fr) * | 2006-08-31 | 2008-04-23 | Novartis AG | Forme crystalline polymorphe d'une dérivé de indan-2-ylamino-hydroxyethyl-quinolinone maleate comme agoniste de 2-adrénorécepteur beta |
BRPI0717564A2 (pt) | 2006-09-29 | 2013-10-22 | Novartis Ag | Pirazolopirimidinas como inibidores de pi3k lipídeo cinase |
CA2667962A1 (fr) | 2006-10-30 | 2008-05-08 | Novartis Ag | Composes heterocycliques en tant qu'agents anti-inflammatoires |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
RS51644B (en) | 2007-01-10 | 2011-10-31 | Irm Llc. | UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
MX2009008493A (es) | 2007-02-09 | 2009-08-20 | Irm Llc | Compuestos y composiciones como inhibidores de la proteasa activadora de canal. |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
WO2009154557A1 (fr) | 2008-06-18 | 2009-12-23 | Astrazeneca Ab | Dérivés de benzoxazinone agissant comme agoniste des récepteurs bêta2-adrénergiques pour le traitement de troubles respiratoires |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
PT2379507E (pt) | 2008-12-30 | 2014-01-21 | Pulmagen Therapeutics Inflammation Ltd | Compostos de sulfonamida para o tratamento de desordens respiratórias |
ES2396023T3 (es) | 2009-01-29 | 2013-02-18 | Novartis Ag | Bencimidazoles sustituidos para el tratamiento de astrocitomas |
AR075401A1 (es) * | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
WO2010150014A1 (fr) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
WO2011020861A1 (fr) | 2009-08-20 | 2011-02-24 | Novartis Ag | Composés d'oximes hétérocycliques |
EP2813227A1 (fr) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
US8877930B2 (en) * | 2009-11-04 | 2014-11-04 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
WO2011098746A1 (fr) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
BR112012020629A2 (pt) * | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
WO2011109276A1 (fr) | 2010-03-01 | 2011-09-09 | Massachussets Institute Of Technology | Catalyseurs d'époxydation |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
BR112013008974A2 (pt) | 2010-10-12 | 2023-12-19 | Cipla Ltd | Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica |
JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
WO2012116237A2 (fr) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Composés hétérocycliques et leurs utilisations |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン |
WO2013038373A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyrimidinamides |
WO2013038378A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyridinamides |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013038381A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés d'amide pyridine/pyrazine |
EP2755652B1 (fr) | 2011-09-16 | 2021-06-02 | Novartis AG | Hétérocyclyle carboxamides n-substitués |
EP2793893A4 (fr) | 2011-11-23 | 2015-07-08 | Intellikine Llc | Régimes de traitement améliorés utilisant des inhibiteurs de mtor |
US20140357641A1 (en) | 2012-01-13 | 2014-12-04 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2802581A1 (fr) | 2012-01-13 | 2014-11-19 | Novartis AG | 7,8-dihydropyrido[3,4-b]pyrazines utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés |
US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
WO2013105066A1 (fr) | 2012-01-13 | 2013-07-18 | Novartis Ag | Sels d'un agoniste du récepteur ip |
EP2802585A1 (fr) | 2012-01-13 | 2014-11-19 | Novartis AG | Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'htap et de troubles connexes |
TW201335160A (zh) | 2012-01-13 | 2013-09-01 | Novartis Ag | Ip受體激動劑之雜環化合物 |
WO2013132514A2 (fr) * | 2012-03-09 | 2013-09-12 | Rao Davuluri Ramamohan | Nouveau procédé de préparation de (r)-5-[2-[(5, 6-diéthyl-2, 3-dihydro-1h-indèn-2-yl) amino]-1-hydroxyéthyl]-8-hydroxy quinoléin-2(1h)-one |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP3964513A1 (fr) | 2012-04-03 | 2022-03-09 | Novartis AG | Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation |
WO2014008639A1 (fr) * | 2012-07-11 | 2014-01-16 | 上海威智医药科技有限公司 | Procédé de préparation d'indacatérol |
WO2014008640A1 (fr) * | 2012-07-11 | 2014-01-16 | 上海威智医药科技有限公司 | Intermédiaire d'indacatérol et procédé de synthèse d'indacatérol |
CN103539677B (zh) * | 2012-07-16 | 2015-04-22 | 武汉万知生物医药有限公司 | 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法 |
EP3138837B1 (fr) | 2012-09-21 | 2021-11-24 | Crystal Pharma, S.A.U. | Base libre d'indacatérol sous forme solide |
WO2014044288A1 (fr) | 2012-09-21 | 2014-03-27 | Crystal Pharma Sa | Procédés de préparation d'indacatérol et de ses sels pharmaceutiquement acceptables |
AU2013365742B2 (en) | 2012-12-19 | 2016-11-24 | Novartis Ag | Autotaxin inhibitors |
US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
JP2016507582A (ja) | 2013-02-13 | 2016-03-10 | ノバルティス アーゲー | Ip受容体アゴニスト複素環式化合物 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
MX2015012529A (es) | 2013-03-14 | 2016-07-05 | Novartis Ag | Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla. |
US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
CZ306252B6 (cs) * | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
WO2014154841A1 (fr) * | 2013-03-27 | 2014-10-02 | Laboratorios Lesvi, S.L. | Procédé pour la fabrication de (r)-5-[2-(5,6-diéthyl-indan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-(1h)-quinolin-2-one |
US20160168119A1 (en) | 2013-07-18 | 2016-06-16 | Novartis Ag | Autotaxin inhibitors |
US9763957B2 (en) | 2013-07-18 | 2017-09-19 | Novartis Ag | Autotaxin inhibitors |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
CN104744360B (zh) * | 2013-12-26 | 2017-02-22 | 成都伊诺达博医药科技有限公司 | 一种合成茚达特罗的新方法 |
PL3092217T3 (pl) | 2014-01-09 | 2020-11-16 | Davuluri, Ramamohan Rao | Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli |
CN103830195A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 一种茚达特罗片及其制备方法 |
CN103830193A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 茚达特罗片制剂及其制备方法 |
CA2940599A1 (fr) | 2014-03-27 | 2015-10-01 | Novartis Ag | Dispersions d'huile-dans-l'eau solides sechees par pulverisation pour l'inhalation de principes pharmaceutiques actifs |
EP3134398A1 (fr) | 2014-04-24 | 2017-03-01 | Novartis Ag | Inhibiteurs de l'autotaxine |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
CN106458979B (zh) | 2014-04-24 | 2020-03-27 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物 |
WO2016011658A1 (fr) | 2014-07-25 | 2016-01-28 | Novartis Ag | Polythérapie |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
DE102014217201A1 (de) | 2014-08-28 | 2016-03-03 | Henkel Ag & Co. Kgaa | Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90 |
DE102014217205A1 (de) | 2014-08-28 | 2016-03-03 | Henkel Ag & Co. Kgaa | Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W |
US11094409B2 (en) | 2015-01-20 | 2021-08-17 | Novartis Ag | Application unlock using a connected physical device and transfer of data therebetween |
ES2758677T3 (es) * | 2015-01-20 | 2020-05-06 | Olon Spa | Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis |
CN107531636B (zh) * | 2015-04-09 | 2022-11-25 | 正大天晴药业集团股份有限公司 | 茚达特罗或其盐的制备方法 |
PT3111978T (pt) | 2015-07-03 | 2021-12-06 | Novartis Ag | Inalador adaptado para ler informação armazenada num meio de armazenamento de dados de um recipiente |
ITUB20153978A1 (it) * | 2015-09-28 | 2017-03-28 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi. |
CN105884626B (zh) * | 2016-05-04 | 2017-10-20 | 龙曦宁(上海)医药科技有限公司 | 一种2‑氨基茚满衍生物的合成方法及其产品 |
CN108101841B (zh) * | 2016-11-24 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种制备茚达特罗或其盐的方法 |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
EP3735406B1 (fr) | 2018-01-02 | 2022-05-11 | Deva Holding Anonim Sirketi | Procédé de préparation de 5-(1-hydroxyéthyle à substitution amino en position 2)-quinoléine-2(1h)-one à substitution oxy en position 8 |
EP3768792B1 (fr) | 2018-03-19 | 2023-09-20 | Dow Silicones Corporation | Composition adhésive thermofusible contenant un copolymère polyoléfine-polydiorganosiloxane et ses procédés de préparation et d'utilisation |
CA3093558A1 (fr) | 2018-03-19 | 2019-09-26 | Dow Silicones Corporation | Compositions adhesives thermofusibles a base de polyorganosiloxane contenant des copolymeres de polyolefine-polydiorganosiloxanes et leurs procedes de preparation et d'utilisation |
KR20200133349A (ko) | 2018-03-19 | 2020-11-27 | 다우 글로벌 테크놀로지스 엘엘씨 | 폴리올레핀 - 폴리디오르가노실록산 블록 공중합체 및 이의 합성을 위한 히드로실릴화 반응 방법 |
CN112334515B (zh) | 2018-07-17 | 2022-08-09 | 美国陶氏有机硅公司 | 聚硅氧烷树脂-聚烯烃共聚物及其制备和使用方法 |
WO2020047225A1 (fr) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Procédés de traitement de bronchopneumopathie chronique obstructive |
KR20210089656A (ko) | 2018-10-05 | 2021-07-16 | 버텍스 파마슈티칼스 인코포레이티드 | 알파-1 항트립신 조절제 |
CN109369417B (zh) * | 2018-10-19 | 2021-07-06 | 诚达药业股份有限公司 | 一种2-氨基茚满衍生物的制备方法 |
WO2020105012A1 (fr) | 2018-11-22 | 2020-05-28 | Glenmark Specialty S.A. | Compositions stériles d'indacatérol appropriées pour la nébulisation |
US20200215051A1 (en) | 2019-01-03 | 2020-07-09 | Glenmark Specialty S.A. | Nebulization composition comprising tiotropium and indacaterol |
CN109896967B (zh) * | 2019-04-04 | 2021-10-22 | 上海工程技术大学 | 一种间二乙氨基苯酚的制备方法 |
CN109896966B (zh) * | 2019-04-04 | 2021-10-22 | 上海工程技术大学 | 一种n,n-二丁基间氨基苯酚的制备方法 |
US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
CN110229078A (zh) * | 2019-05-22 | 2019-09-13 | 博诺康源(北京)药业科技有限公司 | 一种茚达特罗起始原料开环杂质的制备 |
WO2020250116A1 (fr) | 2019-06-10 | 2020-12-17 | Novartis Ag | Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie |
JOP20220044A1 (ar) | 2019-08-28 | 2023-01-30 | Novartis Ag | مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
EP4126819A1 (fr) * | 2020-04-03 | 2023-02-08 | Vertex Pharmaceuticals Incorporated | Dérivés de 7-ou 8-hydroxy-isoquinoléine et de 7-ou 8-hydroxy-quinoléine en tant que modulateurs d'alpha-1-antitrypsine pour traiter une déficience en alpha-1-antitrypsine (aatd) |
AU2021325431B2 (en) | 2020-08-14 | 2024-01-18 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
WO2022073009A1 (fr) | 2020-09-29 | 2022-04-07 | iPharma Labs, Inc. | Formulations liquides d'indacatérol |
CN115677577A (zh) * | 2021-11-03 | 2023-02-03 | 中国药科大学 | 靶向srsf6蛋白的小分子化合物及其制备方法和用途 |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8707123D0 (en) | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
ZA903906B (en) * | 1989-05-25 | 1992-02-26 | Takeda Chemical Industries Ltd | Benzocycloalkane derivatives and production thereof |
AU632809B2 (en) | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
GB9107827D0 (en) * | 1991-04-12 | 1991-05-29 | Fujisawa Pharmaceutical Co | New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
JPH0518007A (ja) | 1991-07-05 | 1993-01-26 | Konoike Constr Ltd | 鉄骨梁との接合部を内蔵したpc柱 |
IL104567A (en) * | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1993018007A1 (fr) * | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
ATE163930T1 (de) | 1993-01-29 | 1998-03-15 | American Cyanamid Co | Aminocycloalkanobenzodioxole als beta-3 selektive adrenergische wirkstoffe |
DK0712387T3 (da) | 1993-08-06 | 2000-05-29 | Upjohn Co | 2-Aminoindaner som selektive dopamin-D3-ligander |
FR2711407B1 (fr) * | 1993-10-19 | 1996-01-26 | Allevard Sa | Perfectionnements aux barres de torsion métalliques. |
US5578638A (en) | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
CN1166622C (zh) | 1995-02-01 | 2004-09-15 | 法玛西雅厄普约翰美国公司 | 作为选择性多巴胺d3配体的2-氨基-1,2-二氢化茚 |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
SG72727A1 (en) * | 1996-02-19 | 2000-05-23 | Kissei Pharmaceutical | 3,4-Disubstituted phenylethanolaminotetralincarboxamide derivatives |
JP3708624B2 (ja) * | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | 3,4−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
JP3690071B2 (ja) | 1997-06-24 | 2005-08-31 | 井関農機株式会社 | ロータリ耕耘具の防護装置 |
WO1999009001A1 (fr) * | 1997-08-19 | 1999-02-25 | Kissei Pharmaceutical Co., Ltd. | Derives de phenylethanolaminotetraline et bronchodilatateurs |
DE69940484D1 (de) | 1998-04-06 | 2009-04-09 | Astellas Pharma Inc | Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie |
DE20122417U1 (de) | 2000-06-27 | 2005-08-04 | Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat | Von Arylalkylaminen abgeleitete Carbamate |
-
1999
- 1999-06-04 GB GBGB9913083.3A patent/GB9913083D0/en not_active Ceased
-
2000
- 2000-05-10 TW TW089108928A patent/TWI253447B/zh active
- 2000-05-26 MY MYPI20002328A patent/MY126951A/en unknown
- 2000-05-29 CO CO00039577A patent/CO5170518A1/es active IP Right Grant
- 2000-06-01 AR ARP000102709A patent/AR035548A1/es active IP Right Grant
- 2000-06-02 CZ CZ20014301A patent/CZ302403B6/cs unknown
- 2000-06-02 DE DE60042781T patent/DE60042781D1/de not_active Expired - Lifetime
- 2000-06-02 TR TR2001/03497T patent/TR200103497T2/xx unknown
- 2000-06-02 WO PCT/EP2000/005058 patent/WO2000075114A1/fr active IP Right Grant
- 2000-06-02 AU AU50745/00A patent/AU765919B2/en active Active
- 2000-06-02 PT PT81715237T patent/PT2332915E/pt unknown
- 2000-06-02 AT AT00935163T patent/ATE440083T1/de active
- 2000-06-02 SI SI200031045T patent/SI1183240T1/sl unknown
- 2000-06-02 SK SK1743-2001A patent/SK287260B6/sk not_active IP Right Cessation
- 2000-06-02 PL PL352100A patent/PL198847B1/pl unknown
- 2000-06-02 DE DE201012000009 patent/DE122010000009I2/de active Active
- 2000-06-02 RU RU2001135801/04A patent/RU2244709C2/ru active Protection Beyond IP Right Term
- 2000-06-02 NZ NZ515669A patent/NZ515669A/xx not_active IP Right Cessation
- 2000-06-02 BR BRPI0011324A patent/BRPI0011324B8/pt not_active IP Right Cessation
- 2000-06-02 HU HU0201658A patent/HU227034B1/hu active Protection Beyond IP Right Term
- 2000-06-02 EP EP00935163A patent/EP1183240B1/fr not_active Expired - Lifetime
- 2000-06-02 CN CNB008084874A patent/CN1156451C/zh not_active Expired - Lifetime
- 2000-06-02 DK DK08171523.7T patent/DK2332915T3/da active
- 2000-06-02 ES ES00935163T patent/ES2331457T3/es not_active Expired - Lifetime
- 2000-06-02 CA CA2375810A patent/CA2375810C/fr not_active Expired - Lifetime
- 2000-06-02 JP JP2001501595A patent/JP3785365B2/ja not_active Expired - Lifetime
- 2000-06-02 PT PT00935163T patent/PT1183240E/pt unknown
- 2000-06-02 DK DK00935163T patent/DK1183240T3/da active
- 2000-06-02 MX MXPA01012474A patent/MXPA01012474A/es active IP Right Grant
- 2000-06-02 PE PE2000000548A patent/PE20010219A1/es not_active IP Right Cessation
- 2000-06-02 US US10/009,008 patent/US6878721B1/en active Active
- 2000-06-02 ES ES08171523T patent/ES2402535T3/es not_active Expired - Lifetime
- 2000-06-02 EP EP08171523A patent/EP2332915B1/fr not_active Expired - Lifetime
- 2000-06-02 IL IL14657800A patent/IL146578A0/xx active IP Right Grant
- 2000-06-02 KR KR1020017015568A patent/KR100718615B1/ko active Protection Beyond IP Right Term
-
2001
- 2001-11-19 IL IL146578A patent/IL146578A/en active Protection Beyond IP Right Term
- 2001-12-03 ZA ZA200109931A patent/ZA200109931B/en unknown
- 2001-12-03 NO NO20015912A patent/NO322944B1/no not_active IP Right Cessation
-
2002
- 2002-07-29 HK HK02105569.8A patent/HK1045837B/zh not_active IP Right Cessation
-
2005
- 2005-03-07 US US11/074,400 patent/US7622483B2/en not_active Expired - Lifetime
-
2009
- 2009-10-13 US US12/577,855 patent/US7820694B2/en not_active Expired - Fee Related
- 2009-11-11 CY CY20091101179T patent/CY1109604T1/el unknown
-
2010
- 2010-02-15 FR FR10C0006C patent/FR10C0006I2/fr active Active
- 2010-02-17 LU LU91651C patent/LU91651I2/fr unknown
- 2010-02-18 NL NL300437C patent/NL300437I1/nl unknown
- 2010-02-24 BE BE2010C011C patent/BE2010C011I2/fr unknown
- 2010-03-09 CY CY2010003C patent/CY2010003I1/el unknown
- 2010-07-02 NO NO2010014C patent/NO2010014I1/no unknown
- 2010-09-20 US US12/885,922 patent/US8067437B2/en not_active Expired - Fee Related
-
2011
- 2011-08-23 HK HK11108894.7A patent/HK1154584A1/xx not_active IP Right Cessation
- 2011-11-14 US US13/295,426 patent/US8283362B2/en not_active Expired - Lifetime
-
2012
- 2012-07-23 US US13/555,536 patent/US8436017B2/en not_active Expired - Fee Related
-
2013
- 2013-04-08 US US13/858,308 patent/US8658673B2/en not_active Expired - Fee Related
- 2013-05-24 CY CY20131100413T patent/CY1114120T1/el unknown
- 2013-11-11 US US14/076,478 patent/US8796307B2/en not_active Expired - Fee Related
-
2014
- 2014-08-04 US US14/450,692 patent/US9040559B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91651I2 (fr) | Produits médicinaux contenent de l'indacatérol ou un sel de celui-ci (ONBREZ BREEZHALER®) | |
LU92397I2 (fr) | Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable | |
HK1033809A1 (en) | Pharmaceutical formulation containing epothilone | |
HUP0203597A3 (en) | Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use | |
IL148379A0 (en) | Pharmaceutical solutions of levosimendan | |
FI970058A (fi) | Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa | |
IL138416A (en) | Use of dexmedetomidine or pharmaceutical acceptable salt thereof for preparation of a sedative | |
PT1202996E (pt) | Compostos de titanio a sua preparacao e a sua utilizacao | |
IL145632A0 (en) | Pharmaceutical compounds | |
GB9916434D0 (en) | Pharmaceutical compounds | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
FR2785785B1 (fr) | Distributeur de produits pour lave-vaisselle | |
PL352062A1 (en) | Oral solution of prucalopride | |
GB9914255D0 (en) | Pharmaceutical compounds | |
HUP0103826A3 (en) | A process for the preparation of zofenopril calcium salt and medicament containing it and its use | |
GB9903784D0 (en) | Pharmaceutical compounds | |
IL148220A0 (en) | Pharmaceutical preparation containing nanosol | |
FR2796047B1 (fr) | Emballage pour le conditionnement d'une preparation alimentaire | |
GB2373499B (en) | Pharmaceutical compounds | |
FR2765474B1 (fr) | Opercule de protection pour les produits d'hygiene feminine | |
FR2789282B3 (fr) | Embrayage pour appareil de traitement d'aliments | |
FR2833582B1 (fr) | Systeme de conditionnement en un materiau semi-rigide de pizzas ou d'articles alimentaires similaires | |
FR2818907B1 (fr) | Utilisation de la brivudine pour la preparation d'une composition pharmaceutique | |
FR2789566B1 (fr) | Systeme d'aide a l'embrochage de produits a rotir | |
ITIS990001A0 (it) | Contenitore flessibile di confetti per l'alimentazione umana. |